Table 2.
Statistics of patient data used for pharmacoepidemiologic analysis
| Group | Sample size | # of AD | Female (%) | Mean Age (SD) | Geographical location (%) | CAD (%) | T2D (%) | HTN (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Northeast | North Central | South | West | NA | ||||||||
| Pioglitazone (repurposing drug), glipizide (comparative drug) and matched control | ||||||||||||
| Pioglitazone | 101,650 | 1244 | 38.5 | 72.8 (6.9) | 17.7 | 28.4 | 35.6 | 17.3 | 0.9 | 11.3 | 51.2 | 34.2 |
| Glipizide | 191,656 | 3048 | 44.8 | 74.2 (7.1) | 21.5 | 27.6 | 31.4 | 18.7 | 0.8 | 17.1 | 59.4 | 43.0 |
| Control | 402,488 | 5230 | 38.3 | 74.5 (7.2) | 24.2 | 31.4 | 30.5 | 13 | 1 | 13.5 | 44.6 | 41.1 |
| Febuxostat (repurposing drug), and matched control | ||||||||||||
| Febuxostat | 24,218 | 243 | 37.2 | 75.1 (7.9) | 23.5 | 23.8 | 37.7 | 14.4 | 0.6 | 28.0 | 35.3 | 58.6 |
| Control | 95,192 | 1168 | 37.0 | 75.7 (7.4) | 24.7 | 31.6 | 30.3 | 12.7 | 0.8 | 26.7 | 34.1 | 58.1 |
| Atenolol (repurposing drug), and matched control | ||||||||||||
| Atenolol | 366,277 | 58 | 74.5 (8.0) | 24 | 26 | 29 | 21 | 0.7 | 11 | 14 | 34 | |
| Control | 1,449,815 | 58 | 75.2 (7.5) | 24 | 30 | 30 | 14 | 1.1 | 12 | 16 | 38 | |
| Nadolol (repurposing drug), and matched control | ||||||||||||
| Nadolol | 19,253 | 60 | 73.7 (7.8) | 29 | 25 | 35 | 10 | 0.8 | 11 | 18 | 34 | |
| Control | 76,136 | 60 | 75.2 (7.5) | 24 | 30 | 30 | 14 | 1.1 | 12 | 19 | 40 | |
| Sotalol (repurposing drug), and matched control | ||||||||||||
| Sotalol | 43,819 | 46 | 76.4 (7.7) | 19 | 29 | 38 | 14 | 0.5 | 35 | 22 | 50 | |
| Control | 172,375 | 46 | 76.1 (7.5) | 25 | 31 | 30 | 13 | 0.8 | 30 | 22 | 50 | |
We estimated the unstratified Kaplan-Meier curves, conducted propensity score stratified (n strata = 10) log-rank test and Cox model. CAD coronary artery disease, T2D type 2 diabetes, HTN hypertension, SD standard deviation